A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobul...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa, Flávia, Cruz, Andrea, Fonte, Pedro, Pinto, Inês Mendes, Neves-Petersen, Maria Teresa, Sarmento, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473878/
https://www.ncbi.nlm.nih.gov/pubmed/28623267
http://dx.doi.org/10.1038/s41598-017-03959-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473878/
https://www.ncbi.nlm.nih.gov/pubmed/28623267
http://dx.doi.org/10.1038/s41598-017-03959-4

Ejemplares similares